IBDEI0RX ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13095,2)
 ;;=^5002831
 ;;^UTILITY(U,$J,358.3,13096,0)
 ;;=E66.9^^53^585^43
 ;;^UTILITY(U,$J,358.3,13096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13096,1,3,0)
 ;;=3^Obesity,Unspec
 ;;^UTILITY(U,$J,358.3,13096,1,4,0)
 ;;=4^E66.9
 ;;^UTILITY(U,$J,358.3,13096,2)
 ;;=^5002832
 ;;^UTILITY(U,$J,358.3,13097,0)
 ;;=E74.39^^53^585^35
 ;;^UTILITY(U,$J,358.3,13097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13097,1,3,0)
 ;;=3^Intestinal Carbohydrate Absorption Disorder NEC
 ;;^UTILITY(U,$J,358.3,13097,1,4,0)
 ;;=4^E74.39
 ;;^UTILITY(U,$J,358.3,13097,2)
 ;;=^5002928
 ;;^UTILITY(U,$J,358.3,13098,0)
 ;;=E83.30^^53^585^46
 ;;^UTILITY(U,$J,358.3,13098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13098,1,3,0)
 ;;=3^Phosphorus Metabolism Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,13098,1,4,0)
 ;;=4^E83.30
 ;;^UTILITY(U,$J,358.3,13098,2)
 ;;=^5002997
 ;;^UTILITY(U,$J,358.3,13099,0)
 ;;=E83.51^^53^585^28
 ;;^UTILITY(U,$J,358.3,13099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13099,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,13099,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,13099,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,13100,0)
 ;;=E83.52^^53^585^26
 ;;^UTILITY(U,$J,358.3,13100,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13100,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,13100,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,13100,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,13101,0)
 ;;=E87.5^^53^585^27
 ;;^UTILITY(U,$J,358.3,13101,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13101,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,13101,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,13101,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,13102,0)
 ;;=E89.2^^53^585^48
 ;;^UTILITY(U,$J,358.3,13102,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13102,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,13102,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,13102,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,13103,0)
 ;;=E89.6^^53^585^47
 ;;^UTILITY(U,$J,358.3,13103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13103,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,13103,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,13103,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,13104,0)
 ;;=L68.0^^53^585^25
 ;;^UTILITY(U,$J,358.3,13104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13104,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,13104,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,13104,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,13105,0)
 ;;=M80.00XA^^53^585^2
 ;;^UTILITY(U,$J,358.3,13105,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13105,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,13105,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,13105,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,13106,0)
 ;;=M81.0^^53^585^3
 ;;^UTILITY(U,$J,358.3,13106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13106,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,13106,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,13106,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,13107,0)
 ;;=M85.80^^53^585^44
 ;;^UTILITY(U,$J,358.3,13107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13107,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,13107,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,13107,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,13108,0)
 ;;=N62.^^53^585^24
 ;;^UTILITY(U,$J,358.3,13108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13108,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,13108,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,13108,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,13109,0)
 ;;=E10.43^^53^585^6
